oncology
Secarna Pharmaceuticals to announce positive new data at cancer research conference
April 1, 2025Research and Development Oncology, Secarna Pharmaceuticals, oncology, research and development
Secarna Pharmaceuticals will present new preclinical data with its lead programme SECN-15 at the American Association for Cancer Research (AACR) …
Pierre Fabre announces investments and partnerships in lung cancer research
March 27, 2025Research and Development Oncology, Pierre Fabre Laboratories, lung cancer treatment, oncology
Pierre Fabre Laboratories has announced investment and partnership plans to improve the lives of lung cancer patients with unmet needs. …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
August 7, 2024Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …
Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour
August 2, 2024Medical Communications Adaptimmune, Oncology, accelerated approval, engineered cell therapy, oncology, synovial sarcoma
Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given accelerated approval for TECELRA (afamitresgene …
Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
July 30, 2024Mergers and Acquisitions Boehringer Ingelheim, Nerio Therapeutics, Oncology, immuno-oncology, oncology
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio Therapeutics for up to $1.3bn, …
AI-powered prognosis test company Spotlight Medical secures €6.2m in seed funding
July 15, 2024Research and Development Oncology, Precision Medicine, Spotlight Medical, artificial intelligence, oncology, seed funding
Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. …
IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer
June 27, 2024Research and Development IDEAYA Biosciences, Oncology, bladder cancer, clinical trials, oncology
Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored phase 1 trial has been …
Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA
June 27, 2024Research and Development MimiVax, Oncology, Orphan Drug Designation, Roswell Park Comprehensive Cancer Center, immunotherapies, oncology
The US Food and Drug Administration (FDA) has granted an expanded Orphan Drug Designation (ODD) for brain cancer immunotherapy SurVaxM, …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
March 26, 2024Research and Development Cancer, Curve Therapeutics, HIF inhibition, Oncology, oncology
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research in the Journal of the …
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
January 4, 2024Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …
Genentech shares positive results from phase 3 trial for breast cancer treatment
December 5, 2023Research and Development Genentech, Oncology, breast cancer, oncology
Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …
Evotec and Dewpoint Therapeutics enter strategic partnership
November 7, 2023Research and Development Dewpoint Therapeutics, Evotec, Oncology, R&D, oncology
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s oncology pipeline programmes of condensate …
First patient dosed in Transgene and BioInvent’s phase 1 trial
October 10, 2023Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial
Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …
BMS acquires Mirati Therapeutics for $4.8bn
October 9, 2023Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …
Eli Lilly to acquire POINT Biopharma
October 4, 2023Business Services Eli Lilly, Oncology, POINT Biopharma, acquisition, oncology
Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of …
Latest content
FibroFind appoints Lee Borthwick as CEO
